Filing Details

Accession Number:
0001610717-23-000406
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-12-19 17:37:12
Reporting Period:
2023-12-15
Accepted Time:
2023-12-19 17:37:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1676725 Ideaya Biosciences Inc. IDYA Pharmaceutical Preparations (2834) 474268251
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1790865 Jason Throne C/O Ideaya Biosciences, Inc.
7000 Shoreline Court, Suite 350
South San Francisco CA 94080
Chief Legal Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-12-15 10,000 $13.34 10,000 No 4 M Direct
Common Stock Disposition 2023-12-15 10,000 $35.04 0 No 4 S Direct
Common Stock Acquisiton 2023-12-18 10,000 $7.01 10,000 No 4 M Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2023-12-15 10,000 $0.00 10,000 $13.34
Common Stock Stock Option (Right to Buy) Disposition 2023-12-18 10,000 $0.00 10,000 $7.01
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
47,610 2030-06-30 No 4 M Direct
48,420 2029-10-08 No 4 M Direct
Footnotes
  1. The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 29, 2023.
  2. This transaction was executed in multiple trades in prices ranging from $35.00 to $35.10, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  3. 25% of the shares subject to the option vest on the first anniversary measured from July 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
  4. The shares subject to the option are fully vested and exercisable.